A Novel Cuproptosis Pattern and Tumor Immune Microenvironment Characterization in Urothelial Carcinoma of the Bladder

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Sep 4

PMID 37662947

Authors

Huan Feng

Zhiyao Deng

Yibao Huang

Zhuo Liu

Yajun Ruan

Tao Wang

Jihong Liu

Affiliations

Soon will be listed here.

Abstract

Background: Urothelial carcinoma of the bladder (UCB) is the most prevalent malignant tumor of the urinary system worldwide, which has a significant recurrence rate despite multiple treatment options available. As a unique and novel copper-dependent programmed cell death mechanism, the comprehensive impact of cuproptosis on the tumor immune microenvironment, clinicopathological characteristics and the prognosis of patients remains largely unclear.

Methods: A total of 568 UCB samples were thoroughly examined for cuproptosis patterns using data downloaded from TCGA and GEO, based on 10 cuproptosis-related genes reported previously. Then, the univariate COX regression analysis was performed on the genes that differed across the various patterns. To measure individual cuproptosis pattern, a cuproptosis score system was constructed using a principal component analysis algorithm. To validate the scoring system, immunohistochemical staining was performed on tumor tissues with different pathological grades, and experiments were conducted about the differentially expressed genes related to prognosis. Finally, the capacity of scoring system to predict the response to immunotherapy was verified by using data from IMvigor 210 cohort.

Results: Four unique cuproptosis clusters and two gene clusters were finally found by the investigation. The clinical features and prognosis of patients, as well as the mRNA transcriptome, pathway enrichment, and immune cell infiltration in TME, varied dramatically between various cuproptosis clusters and gene clusters. To identify individual cuproptosis patterns in UCB patients, we also established a cuproptosis scoring system. After validation with multiple methods, it was indicated that the score system could predict the prognosis of UCB patients and was significantly connected to clinical features such TNM category, tumor grade, molecular type and ultimate survival status. The clinical outcomes of UCB patients were predicted effectively according to the tumor mutation burden in conjunction with the scoring system. Furthermore, we found that the cuproptosis score had a significant correlation with the response to immunotherapy and the sensitivity to chemotherapy.

Conclusion: This study revealed the potential impact of cuproptosis on the UCB tumor immune microenvironment and clinical pathological characteristics. The cuproptosis score system could effectively predict the prognosis of patients and the response to chemotherapy and immunotherapy.

References

Jin M, Jin W . The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020; 5(1):166. PMC: 7447642. DOI: 10.1038/s41392-020-00280-x. View

Conway J, Kofman E, Mo S, Elmarakeby H, Van Allen E . Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Med. 2018; 10(1):93. PMC: 6264032. DOI: 10.1186/s13073-018-0605-7. View

Yuan H, Liu J, Zhao L, Wu P, Chen G, Chen Q . Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma. Front Immunol. 2021; 12:800268. PMC: 8692582. DOI: 10.3389/fimmu.2021.800268. View

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

Ji Z, Ren W, Wang H, Gao W, Yuan B . Molecular Subtyping Based on Cuproptosis-Related Genes and Characterization of Tumor Microenvironment Infiltration in Kidney Renal Clear Cell Carcinoma. Front Oncol. 2022; 12:919083. PMC: 9299088. DOI: 10.3389/fonc.2022.919083. View

Soloway M, Sofer M, Vaidya A . Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol. 2002; 167(4):1573-83. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

Manzano R, Catalan-Latorre A, Brugarolas A . RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer. BMC Cancer. 2021; 21(1):432. PMC: 8056512. DOI: 10.1186/s12885-021-08078-y. View

Shanbhag V, Gudekar N, Jasmer K, Papageorgiou C, Singh K, Petris M . Copper metabolism as a unique vulnerability in cancer. Biochim Biophys Acta Mol Cell Res. 2020; 1868(2):118893. PMC: 7779655. DOI: 10.1016/j.bbamcr.2020.118893. View

10.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

11.

Yang L, Yu J, Tao L, Huang H, Gao Y, Yao J . Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. Front Genet. 2022; 13:947551. PMC: 9354258. DOI: 10.3389/fgene.2022.947551. View

12.

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

13.

Lelievre P, Sancey L, Coll J, Deniaud A, Busser B . The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy. Cancers (Basel). 2020; 12(12). PMC: 7760327. DOI: 10.3390/cancers12123594. View

14.

Oliveri V . Selective Targeting of Cancer Cells by Copper Ionophores: An Overview. Front Mol Biosci. 2022; 9:841814. PMC: 8931543. DOI: 10.3389/fmolb.2022.841814. View

15.

Tang D, Kang R, Vanden Berghe T, Vandenabeele P, Kroemer G . The molecular machinery of regulated cell death. Cell Res. 2019; 29(5):347-364. PMC: 6796845. DOI: 10.1038/s41422-019-0164-5. View

16.

Ge E, Bush A, Casini A, Cobine P, Cross J, DeNicola G . Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2021; 22(2):102-113. PMC: 8810673. DOI: 10.1038/s41568-021-00417-2. View

17.

Koren E, Fuchs Y . Modes of Regulated Cell Death in Cancer. Cancer Discov. 2021; 11(2):245-265. DOI: 10.1158/2159-8290.CD-20-0789. View

18.

Cao Y, Tian T, Li W, Xu H, Zhan C, Wu X . Long non-coding RNA in bladder cancer. Clin Chim Acta. 2020; 503:113-121. DOI: 10.1016/j.cca.2020.01.008. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Cathomas R, Lorch A, Bruins H, Comperat E, Cowan N, Efstathiou J . The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. Eur Urol. 2021; 81(1):95-103. DOI: 10.1016/j.eururo.2021.09.026. View